Get RENX On Your Radar Right Now

  My Single Highest Conviction Idea Every Morning

*together with RenX Enterprises Corp

Hey everyone,

I want you to get RENX up on your radar right now.

This is one of those lower-priced healthcare names that could start getting attention from traders because it has a real story behind it, a defined medical market, and a stock chart that can move quickly when volume comes in.

The company behind the story is Renalytix, a diagnostics-focused healthcare company working in kidney disease risk assessment. Its main platform, KidneyIntelX.dkd, is designed to help identify which adult patients with type 2 diabetes and chronic kidney disease are at higher risk of progressive kidney function decline.

That matters because kidney disease is a massive healthcare problem, especially among diabetic patients. The bull-case narrative here is simple: if doctors, health systems, and payers use a tool that can identify higher-risk patients earlier, it may help improve care decisions before kidney disease progresses into more expensive and dangerous stages.

Now here is why this needs to be on watch.

One of the biggest news items around Renalytix was the Medicare final coverage determination for KidneyIntelX.dkd. That is important because reimbursement is a major hurdle for diagnostic companies. A test can have an interesting medical use case, but if doctors and healthcare systems do not have a clear path for coverage and payment, adoption can be much harder. Medicare coverage gives the RENX/Renalytix story a stronger fundamental angle than the average speculative penny stock.

Another key headline to understand is the company’s Nasdaq listing-compliance issue. Renalytix previously received notices tied to Nasdaq’s minimum bid price and market value requirements, and the company disclosed that it planned to appeal and present a strategic compliance plan. That is not something to ignore. It adds risk. But in penny-stock land, listing-compliance headlines can also create volatility, attention, and sharp technical moves if traders believe the company has a path to stay listed or regain compliance.

The third piece to watch is the broader healthcare AI and diagnostics theme. Renalytix sits in a niche that combines diagnostics, kidney disease, risk scoring, and clinical decision support. That is the type of theme that can attract momentum traders when volume starts building, especially if the company drops a fresh update around reimbursement, adoption, partnerships, testing volume, or financial runway.

Fundamentally, the attractive part of the RENX story is that it is not just a random shell or hype ticker. There is a real product focus, a large addressable market, and a clear medical need. Chronic kidney disease tied to diabetes is a serious and costly problem, and tools that help identify high-risk patients earlier can be valuable if adoption grows.

At the same time, this is still a speculative name. Traders need to understand the risks: small-cap healthcare stocks can be volatile, cash position matters, dilution risk is always something to watch, and listing-compliance issues can create uncertainty. That is why this is a radar name, not a blind chase.

On the technical side, the first thing I would watch is volume. RENX needs volume expansion to confirm that traders are actually paying attention. A move without volume is less meaningful. A move with unusually strong relative volume can be the first sign that momentum traders are starting to pile in.

The next thing to watch is whether the stock can reclaim and hold key short-term moving averages. If RENX starts holding above prior resistance and building higher lows, that can be a sign the trend is shifting from dead money to active momentum.

The cleanest technical setup would be a break above recent resistance, followed by a hold above that breakout level. That kind of move tells you buyers are not just creating a one-candle spike, but are defending the move. On the other hand, if it spikes and immediately gives the move back, that is usually a warning sign in penny stocks.

Also watch the prior high, the opening range high, VWAP, and the day’s volume pace. If RENX starts trading above VWAP, holds dips, and volume keeps expanding, it becomes much more interesting from a momentum standpoint. If it loses VWAP and volume fades, patience is usually the better move.

Bottom line: RENX is a name I want on the radar because it has a healthcare diagnostics story, a Medicare coverage angle, a kidney disease market opportunity, and the kind of low-priced setup that can move fast when traders start paying attention.

I am not telling you to buy or sell it.

I am saying this is exactly the type of penny stock setup you want to watch closely before the crowd fully catches on.

Keep RENX on your screen today and watch for volume, VWAP strength, a break of resistance, and any fresh company update that could bring new attention into the name.

 P.S. If you would like to see if you have any credits you can apply to any of my services, please reach out to our team at [email protected] or call us at 800-585-4488.